Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Alfatide Ⅱ PET/CT in breast cancer patients
NCT02582801Phase 1Terminated
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of 18f-alfatide in breast cancer (2 arms). Primary endpoint: Maximum standardized uptake value at 1 day. Started Oct 2015; status: terminated.
02
Drugs
18f-alfatide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02582801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582801.